Prospective, Randomised, Open Label, Multicentre Phase II Clinical Trial to Investigate the Efficacy and Safety of the Treatment of Large Cartilage Knee Defects(4-10 cm²) With 3 Diff. Doses of the ACT Product co.Don Chondrosphere®

Trial Profile

Prospective, Randomised, Open Label, Multicentre Phase II Clinical Trial to Investigate the Efficacy and Safety of the Treatment of Large Cartilage Knee Defects(4-10 cm²) With 3 Diff. Doses of the ACT Product co.Don Chondrosphere®

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Autologous cultured chondrocytes (Primary)
  • Indications Knee injuries
  • Focus Therapeutic Use
  • Sponsors co.don AG
  • Most Recent Events

    • 16 Apr 2018 New trial record
    • 05 Apr 2018 According to the co.don AG media release, interim results collected annually over the four-year follow-up period and five-year follow-up examination was carried out for the last patient in early 2018, which was followed by final statistical analysis and evaluation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top